Overall, we demonstrate that combining SA protection to prevent antibody denaturation with competitive NIS inhibition by SP for greater tumor-selective <sup>211</sup>At delivery is feasible, broadens the therapeutic window, and facilitates the clinical application of <sup>211</sup>At-RIT in cancer treatment. The gene discussed is SLC5A5; the disease is cancer.